table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab CORIMUNO-SARI-1 ... ARI-RAF ... REMAP-CAP sarilumab sarilumab Sanofi phase 3 outside US sarilumab Sanofi phase 3 US
sarilumab high dose (400mg) sarilumab phase 2 high dose Lescure ...
sarilumab low dose (200mg) sarimulab phase 2 low dose Lescure ...
tocilizumab Tsai EU-CTR2020-001375-32 ... HNF Hospital Tocilizumab multidisciplinary team EU-CTR2020-001748-24 ... RCT-TCZ-COVID-19 Rutgers NCT04479358 ... Colaneri SAM-COVID-19 NCT04434717 ... Martinez-Sanz RECOVERY NCT04412772 ... EMPACTA Declercq J ... Dongsheng Wang Soin AS ... NCT04577534 ... BACC Bay Tocilizumab Trial TOCOVID Capra Somers Rashad Karakike ... Biran REMAP-CAP ... Talaschian Belhassen-Garc??a Sarhan Veiga Hamed Sarhan TOCI-RAF Study Group ... Mathilde Karampitsakos CORIMUNO-TOCI-ICU ... Andrew COVACTA ... NCT04377750 ... Rojas-Marte Pereira Rosas ... MARIPOSA CORIMUNO-TOCI-1 ...

4 studies excluded by filtering options 2

5123 Gritti et al., 2020 2300excludednot a RCTrisk of bias not avaialble
5494 BREATH-19 Study, 0 2300excludednot a RCTrisk of bias not avaialble
5632 Holt, 2020 2130excludednot a RCTrisk of bias not avaialble
5672 Klopfenstein, 2020 2134excludednot a RCThigh risk of bias

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons